Cyclosporine pharmacokinetics and risk of recurrent rejection in recipients of simultaneous pancreas/kidney transplants

Therapeutic Drug Monitoring

Volumn 18, Issue 5, 1996, Pages 556-561

  Kaplan, Bruce ^a   Wang, Zhao ^a   Abecassis, Michael ^a   Stuart, Frank P ^a   Kaufman, Dixon B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cyclosporine; Kidney; Pancreas; Pharmacokinetics; Rejection; Transplant

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; OKT 3; PREDNISONE; THYMOCYTE ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; RECURRENCE; RISK;

EID: 0029764804     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199610000-00006     Document Type: Article

References (28)

1. Sutherland DER, Morrow CE, Fryd DS, et al. Improved patient and primary renal allograft survival in uremic diabetic recipients. Transplantation 1982;34:319-23.
2. Hedman L, Frisk B, Brynger H, et al. Severe kidney graft rejection in combined kidney and pancreas transplantation. Transplant Proc 1987;19:3911-2.
3. Frisk B, Hedman L, Anderson C, et al. Discrepancy between renal and pancreatic rejection in combined transplantation. Transplant Proc 1989;21:2835-6.
4. Sollinger HW, Stratta RJ, D'Alessandro AM, et al. Experience with simultaneous pancreas-kidney transplantation. Ann Surg 1988;208:475-83.
5. Cheung AHS, Sutherland DER, Gillingham KJ, et al. Simultaneous pancreas-kidney transplant versus kidney transplant alone in diabetic patients. Kidney Int 1992;41:924-9.
6. Klima G, Königsrainer A, Schmid T, et al. Is the pancreas rejected independently of the kidney after combined pancreatic-renal transplantation? Transplant Proc 1988;4:665-7.
7. Wilson TG, Hawthorne WJ, Greenberg MI, et al. Are kidney and pancreas rejection simultaneous events in combined transplants in dogs? Transplant Proc 1990;22:2159-60.
8. Rice JC, Curtis JJ, Laskow DA, Botero-Velez M. Preferential rejection of the kidney in a simultaneous kidney-pancreas transplant. J Am Soc Nephrol 1994;4:1841-6.
9. Grevel J. Absorption of cyclosporine A after oral dosing. Transplant Proc 1986;18(suppl 5):9-15.
10. Lemaire MA, Fahr A, Maurer G. Pharmacokinetics of cyclosporine: inter- and intraindividual variations and metabolic pathways. Transplant Proc 1990;22:1110-2.
11. Dawidson I, Lu C, Ar'Rajab A, Rossi P, Melone D, Wheeler D. Cyclosporine levels predict the likelihood of rejection after simultaneous pancreas/kidney transplantation. Transplant Proc 1994;26:534.
12. Savoldi S, Kahan BD. Relationship of cyclosporine pharmacokinetic parameters to clinical events in human renal transplantation. Transplant Proc 1986;18:120-8.
13. Kasiske BL, Heim-Duthoy K, Rao KV, Awni WM. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. Transplantation 1988;46:716-22.
14. Meyer MM, Munar M, Udeaja J, Bennett W. Efficacy of area under the curve cyclosporine monitoring in renal transplantation. J Am Soc Nephrol 1993;4:1306-15.
15. Grevel J, Welsh MS, Kahan BD. Cyclosporine monitoring renal transplantation: area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit 1989; 11:246-8.
16. Kahan BD. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 1985;5:457-76.
17. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988;46:631-44.
18. Awni WM, Heim-Duthoy K, Kasiske BL. Monitoring of cyclosporine by serial posttransplant pharmacokinetic studies in renal transplant patients. Transplant Proc 1990;22: 1343-4.
19. Munda R, Schroeder TJ, Pedersen SA, et al. Cyclosporine pharmacokinetics in pancreas transplant recipients. Transplant Proc 1988;20(suppl 2):487-90.
20. Kabra PM, Wall JH, Blanckeart N. Solid phase extraction and liquid chromatography for improved assay of cyclosporine in whole blood or plasma. Clin Chem 1985; 31:1717-20.
21. Jacquez JA. Compartmental analysis in medicine and biology. 3rd ed. Ann Arbor: University of Michigan Press, 1995:7.
22. Yee G, Salomon DR. Cyclosporine. In: Evans W, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics. 3rd ed. Vancouver, WA: Applied Therapeutics, 1992: Chapter 28, pp. 1-40.
23. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetic parameters, trough concentrations and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993;54:205-18.
24. Lindholm A, Napoli K, Rutzky L, Kahan BD. Specific monoclonal radioimmunoassay and fluorescence polarization immunoassay for trough concentration and area-under-the-curve monitoring of cyclosporine in renal transplantation. Ther Drug Monit 1992;14:292-300.
25. Cooney GF, Heifets M, Bell A, Shaw LM, Libeth G. Utility of pretransplantation cyclosporine pharmacokinetic studies. Ther Drug Monit 1994;16:151-4.
26. Kaplan B, Wang Z, Kelani T, Kaufman DB. The specificity of monoclonal fluorescence polarization immunoassay for cyclosporine in recipients of simultaneous pancreas kidney transplants. Ther Drug Monit 1995;17:499-500.
27. Johnson A, Sketris I, Marsden JT, et al. A limited sampling strategy for the measurement of cyclosporine AUC. Transplant Proc 1990;22:1345-6.
28. Cantarovich F, Bizollon C, Cantarovich D, LeFrancois N, Dubernard JM, Traeger J. Cyclosporine plasma levels 6 hours after oral administration: a useful tool for monitoring therapy. Transplantation 1988;45:389-94.